Naphyrone (naphthylpyrovalerone): Pharmacokinetics, behavioural effects and thermoregulation in Wistar rats
Nikola Pinterová, Rachel R. Horsley, Hynek Danda, Monika Židková, Eva Lhotková, Klára Šíchová, Kristýna Štefková, Marie Balı́ková, Martin Kuchař, Tomáš Páleníček
Addiction Biology May 7, 2020 DOI: 10.1111/adb.12906 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | In vivo pharmacokinetic and behavioral study Peer reviewed |
|---|---|
| Population | Male Wistar rats |
| Intervention | Naphyrone |
| Dose | 1 mg/kg, 20 mg/kg, 5, 10 or 20 mg/kg |
| Duration | 6 h for pharmacokinetics; 10 h for temperature; behavioral testing at 15 or 60 min post-dose |
| Measures | Open field, Prepulse inhibition (PPI) |
| Keywords | Pharmacokinetics Pharmacology Open field In vivo Thermoregulation Cathinone Stimulation Dopamine |
| Citations | 13 |
| Key points | Naphyrone crosses the blood-brain barrier rapidly, is eliminated slowly, and produces long-lasting hyperlocomotion and modest hyperthermia without acute toxicity. |
Abstract
Naphthylpyrovalerone (naphyrone) is a pyrovalerone cathinone that potently inhibits monoamine transporters and provides stimulatory-entactogenic effects. Little is known about the safety of naphyrone or its effects in vivo, and more research is needed to acquire knowledge about its fundamental effects on physiology and behaviour. Our objective was to investigate naphyrone's pharmacokinetics, acute toxicity, hyperthermic potential and stimulatory and psychotomimetic properties in vivo in male Wistar rats. Pharmacokinetics after 1 mg/kg subcutaneous (sc.) naphyrone were measured over 6 h in serum, the brain, liver and lungs. Rectal temperature (degree Celsius) was measured over 10 h in group-versus individually housed rats after 20 mg/kg sc. In the behavioural experiments, 5, 10 or 20 mg/kg of naphyrone was administered 15 or 60 min prior to testing. Stimulation was assessed in the open field, and sensorimotor processing in a prepulse inhibition (PPI) task. Peak concentrations of naphyrone in serum and tissue were reached at 30 min, with a long-lasting elevation in the brain/serum ratio, consistent with observations of lasting hyperlocomotion in the open field and modest increases in body temperature. Administration of 20 mg/kg transiently enhanced PPI. Naphyrone crosses the blood-brain barrier rapidly and is eliminated slowly, and its long-lasting effects correspond to its pharmacokinetics. No specific signs of acute toxicity were observed; therefore, clinical care and harm-reduction guidance should be in line with that available for other stimulants and cathinones.
Citations in the library
Cited by 4
- Pharmacokinetic, pharmacodynamic, and behavioural studies of deschloroketamine in Wistar rats. British Journal of Pharmacology 2022
- Pharmacokinetics, systemic toxicity, thermoregulation and acute behavioural effects of 25CN‐NBOMe Addiction Biology August 4, 2022
- The acute effects of methoxphenidine on behaviour and pharmacokinetics profile in animal model. Progress in Neuro-Psychopharmacology and Biological Psychiatry March 20, 2025
- Behavioural and pharmacological evaluation of the psilocybin analogue baeocystin in Wistar rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry July 5, 2025
Cites 12
- Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signalling Swiss Medical Weekly January 11, 2015
- Pharmacokinetic, Ambulatory, and Hyperthermic Effects of 3,4-Methylenedioxy-N-Methylcathinone (Methylone) in Rats Frontiers in Psychiatry November 17, 2017
- Contrasting effects of d-methamphetamine, 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxypyrovalerone, and 4-methylmethcathinone on wheel activity in rats Drug and Alcohol Dependence June 3, 2012
- Detailed pharmacological evaluation of methoxetamine (MXE), a novel psychoactive ketamine analogue—Behavioural, pharmacokinetic and metabolic studies in the Wistar rat Brain Research Bulletin May 4, 2016
- Relation of sex and estrous phase to deficits in prepulse inhibition of the startle response induced by ecstasy (MDMA) Behavioural Pharmacology March 1, 2005
and 7 more in the library